Brief: Precision Biosciences Announces Approval Of First Clinical Trial Application Of Arcus Gene Insertion Program By Partner iECURE
13/12/2023 13:43
Dec 13 (Reuters) - Precision BioSciences Inc DTIL.O :
* PRECISION BIOSCIENCES ANNOUNCES APPROVAL OF FIRST CLINICAL
TRIAL
APPLICATION OF ARCUS GENE INSERTION PROGRAM BY PARTNER IECURE
* PRECISION BIOSCIENCES INC: FOR HEPATITIS B VIRUS PROGRAM
ANTICIPATED CLINICAL TRIAL APPLICATION AND/OR INVESTIGATIONAL
NEW DRUG FILING IN 2024.
Source text for Eikon: ID:nBw8Z3MF6a
Further company coverage: DTIL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Precision Biosciences
See all newsPrecision BioSciences Inc reports results for the quarter ended June 30 - Earnings Summary
Precision BioSciences Q2 net loss widens on warrant liability charge
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Brief: Precision Biosciences - Enters First Amendment To Loan And Security Agreement With Banc Of California - SEC Filing